knowledge -WSS

knowledge

author：hotspot 2025-10-01 11:46:20 - browse：26345

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： A fraught question for the kids of Alzheimer’s: Is it coming for us?

entertainment

explore

WSS

Assistant physicians can help address the primary care shortage

Readout LOUD podcast: Merger Mondays, Ozempic panic

What happened to the House vote on health price transparency?

Humana CEO Bruce Broussard to step down in 2024

STAT Readout: Today's biotech news includes Sana and Amylyx

Covid’s new normal has set in amid another rise in cases

focus

knowledge

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

In age of alternative facts, a scholarly course on calling out crap

Patients, doctors press FTC to beef up hospital merger scrutiny

Medical records are filled with copy

European regulators consider appeal over Amylyx ALS drug

DIEP, the 'gold standard' of breast reconstruction, is under threat

European regulators recommend Amylyx's ALS drug be rejected

The high cost of giving birth even with insurance

Medicare to pay more for cardiac rehab in hospital outpatient clinics

knowledge

Midwives could help bridge maternal health disparities in the U.S.

Chamber of Commerce, DOJ clash in court over drug prices

House panel takes first step toward fixing drug shortages

Akili changes sales model for its ADHD video game treatment

Akili changes sales model for its ADHD video game treatment

Akero's treatment for NASH falls short in cirrhosis study

entertainment

explore

Wikipedia

hotspot